Skip to main content

Table 2 Clinical and drug related characteristics of people living with HIV/AIDS at follow up in Jimma health centre ART clinic, April 01 to May 30, 2016

From: Prevalence and predictors of metabolic syndrome among people living with human immunodeficiency virus (PLWHIV)

Variables

Frequency N = 268 (%)

History of BP measured by health workers

 No

151 (56.3)

 Yes

117 (43.7)

Period of blood pressure measured

 The past 12 months

98 (36.6)

 Within past 1–5 years

16 (6.0)

 More than past 5 years

3 (1.1)

Previous history of hypertension

 No

251 (93.7)

 Yes

17 (6.3)

Taking antihypertensive agent past 2 weeks

 No

16 (4.5)

 Yes

5 (1.9)

Previous history of asthma

 No

259 (96.6)

 Yes

9 (3.4)

Previous history of chronic kidney diseases

 No

265 (98.9)

 Yes

3 (1.1)

Duration of HIV diagnosis

 ≤ 5 years

122 (45.5)

 ≥ 6 years

146 (54.5)

CD4 (cell/mm3)

 < 350

223 (83.2)

 351–550

38 (14.2)

 ≥ 551

7 (2.6)

WHO stage

 I

48 (17.9)

 II

129 (48.1)

 III

83 (31)

 IV

8 (3)

OIs prior to HIV diagnosis

 Yes

226 (84.3)

 No

42 (15.7)

Types of cART regimes at baselines

 D-drugsa

92 (34.3)

 Othersb

176 (65.7)

Duration of cART (years)

 ≤ 5

163 (60.8)

 ≥ 6

99 (36.9)

 Othersc

6 (2.2)

Concomitants drug use

 Cotrimoxazole

141 (52.6)

 INH

30 (11.2)

 Multivitamins

6 (2.2)

 Othersd

13 (4.9)

  1. BP blood pressure, HIV human immunodeficiency virus, CD4 cluster differentiation 4, OIs opportunistic infections, URTIs upper respiratory tract infections, cART combination antiretroviral therapy, d4T stavudine, 3TC lamivudine, AZT zidovudine, TDF tenofovir, NVP nevirapine, EVF efavirenz, INH isoniazid
  2. ad4T + 3TC + NVP; d4T + 3TC + EVF
  3. bAZT + 3TC + NVP; AZT + 3TC + EVF; TDF + 3TC + EVF; TDF + 3TC + NVP
  4. cNaïve patients
  5. dEnalapril, hydrochlorothiazide, atenolol, prednisolone, salbutamol puff